Hasil Pencarian - Martin Reck

Perbaiki Hasil
  1. 1
    First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

    First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology oleh Martin Sebastian, Alexander Schmittel, Martin Reck

    Diterbitkan 2014-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects oleh Solange Peters, Roy S Herbst, Martin Reck, Luis Paz-Ares

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression

    Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression oleh Sebastian Marwitz, Swetlana Scheufele, Sven Perner, Martin Reck, Ole Ammerpohl, Torsten Goldmann

    Diterbitkan 2017-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

    Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review oleh Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.

    Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC. oleh Virginie Westeel, Wolfgang Schuette, Thierry Urban, Dejan Radonjic, Ute von Wangenheim, Robert M Lorence, Martin Reck

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis

    Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis oleh Torsten Goldmann, Gernot Zissel, Henrik Watz, Daniel Drömann, Martin Reck, Christian Kugler, Klaus F. Rabe, Sebastian Marwitz

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression

    Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression oleh Sebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, Dörte Nitschkowski, Christian Kugler, Sven Perner, Martin Reck, Ole Ammerpohl, Torsten Goldmann

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

    Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel oleh Julien Mazières, Solange Peters, Andrés Cardona, Martin Reck, David Gandara, Denis Moro-Sibilot, Shirish Gadgeel, Stefanie Morris, Diana Mendus, Marcus Ballinger, Achim Rittmeyer

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

    The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC oleh Sebastian Marwitz, Sebastian Marwitz, Kati Turkowski, Kati Turkowski, Dörte Nitschkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Michael Thomas, Martin Reck, Martin Reck, Daniel Drömann, Daniel Drömann, Werner Seeger, Werner Seeger, Klaus F. Rabe, Klaus F. Rabe, Rajkumar Savai, Rajkumar Savai, Rajkumar Savai, Torsten Goldmann, Torsten Goldmann

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

    Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) oleh Solange Peters, Peter R. Galle, Coen A. Bernaards, Marcus Ballinger, René Bruno, Valerie Quarmby, Jane Ruppel, Alexandr Vilimovskij, Benjamin Wu, Nitzan Sternheim, Martin Reck

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

    ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer oleh Enriqueta Felip, Solange Peters, Alfredo Addeo, Martin Reck, Antonio Passaro, Christophe Von Garnier, Fiona Blackhall, David Planchard, Rafal Dziadziuszko, Filippo de Marinis, Hasna Bouchaab

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas

    Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas oleh Helen Pasternack, Christiane Kuempers, Mario Deng, Iris Watermann, Till Olchers, Mark Kuehnel, Danny Jonigk, Christian Kugler, Florian Stellmacher, Torsten Goldmann, Jutta Kirfel, Ole Ammerpohl, Sven Perner, Martin Reck

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer oleh Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV

    Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stag... oleh Wolfgang M Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H Ficker, Eckart Laack

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Afatinib as first-line treatment in patients with -mutated non-small cell lung cancer in routine clinical practice

    Afatinib as first-line treatment in patients with -mutated non-small cell lung cancer in routine clinical practice oleh Wolfgang M. Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker, Christopher Hoffmann, Andrea Schüler, Eckart Laack

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis

    Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis oleh Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan, Simone Bauer, Florian Janke, Simon John Ogrodnik, Martin Reck, Matthias Schlesner, Michael Meister, Marc A. Schneider, Steffen Dietz, Albrecht Stenzinger, Michael Thomas, Holger Sültmann

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the pha... oleh Eugene Kim, Federico Cappuzzo, Martin Reck, Wei Zou, Mark A Socinski, Mark McCleland, Makoto Nishio, Stefanie Morris, David Shames, Meghna Das Thakur, Tony SK Mok, Howard Jack West, Robert M Jotte, Geetha Shankar

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

    Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials oleh Narikazu Boku, Amit Roy, Yan Feng, Paul Nghiem, Yoon-Koo Kang, Martin Reck, Li-Tzong Chen, Taofeek K Owonikoko, Hye Ryun Kim, Ming Lei, Gregory Plautz, Han Chang, Wen Hong Lin, Akintunde Bello, Jennifer Sheng

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC

    601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel... oleh Aditi Qamra, Hartmut Koeppen, Fabrice Barlesi, Federico Cappuzzo, Martin Reck, Mark A Socinski, Marcus Ballinger, Robert M Jotte, Barzin Nabet, Minu K Srivastava, Soren Muller, Tianshi Lu, Howard West, Habib Hamidi, Assaf Amitai, David S Shames

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

    nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) oleh Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, Pieter E. Postmus, Jaafar Bennouna, Jürgen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Denis Talbot, Ramaswamy Govindan, Teng Jin Ong

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: